Paju-si, South Korea

Mase Lee

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mase Lee - Innovator in Autoimmune Disease Treatment

Introduction

Mase Lee is a notable inventor based in Paju-si, South Korea. He has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. His innovative approach combines advanced pharmaceutical techniques with a focus on patient care.

Latest Patents

Mase Lee holds a patent for a "Sustained formulation for prevention or treatment of autoimmune disease containing naltrexone and method using the same." This patent describes a sustained formulation that includes microparticles comprising naltrexone or its pharmaceutically acceptable salts, along with biodegradable polymers. The formulation is designed to prevent or treat autoimmune diseases over an extended period with a single administration, showcasing a significant advancement in therapeutic methods.

Career Highlights

Throughout his career, Mase Lee has demonstrated a commitment to innovation in the pharmaceutical industry. His work at Inventage Lab Inc. has positioned him as a key player in developing new treatment options for patients suffering from autoimmune conditions. His dedication to research and development has led to breakthroughs that could improve the quality of life for many individuals.

Collaborations

Mase Lee collaborates with talented professionals in his field, including Ju Hee Kim and Donghoon Kim. These partnerships enhance the research and development process, allowing for a more comprehensive approach to tackling complex medical challenges.

Conclusion

Mase Lee's contributions to the field of autoimmune disease treatment through his innovative patent highlight his role as a leading inventor. His work not only advances medical science but also offers hope for patients in need of effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…